News

Women with multiple sclerosis had a greater risk of macrovascular disease than men, which was consistent with previous studies.

The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital gives an overview on what neurologic disorders the new center will focus on.

During the COVID-19 pandemic, it is more important than ever to ensure that a patient with stroke is transferred to the right hospital the first time around.

With an FDA decision on a BLA for the Genentech agent expected later this year, the Group Medical Director of Neuroscience at Genentech shared insight on recent findings of satralizumab in NMOSD.

The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.

Artificial intelligence unlocks new potential to expand neuroimaging tools and techniques available for disease detection and prevention.

Neurology News Network for the week ending May 16, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

The director of pediatric epilepsy and professor of neurology at Mayo Clinic detailed how care for patients with epilepsy has changed during the COVID-19 pandemic.

A cross-sectional, case-control study’s findings imply that patients with epilepsy may be experiencing high rates of psychological distress amid the COVID-19 pandemic.

The data from the SAkuraStar study on satralizumab add to the total literature on the Genentech humanized monoclonal antibody, which is set for FDA decision later this year.

Finkel discussed his new role at St. Jude Children’s Research Hospital, where he'll head up the new Center for Experimental Neurotherapeutics.

Evidence continues to increase on the neurological impacts of COVID-19 infection, with patients admitted to the intensive care unit (ICU) showing brain abnormalities on MRI scans.

Automated Imaging Differentiation in Parkinsonism (AID-P) outperformed both the Magnetic Resonance Parkinsonism Index and neurofilament light chain protein in differentiating PD from atypical parkinsonism.

Pharmazz, the developer of the endothelin-B receptor agonist, noted that it plans to move forward with an investigational new drug submission to the FDA for sovateltide.